|
Synonyms: Anxu® (China) | example 5 [US10561657B2] | TQ-05105 | TQ05105
rovadicitinib is an approved drug
Compound class:
Synthetic organic
Comment: This is the chemical structure for the INN rovadicitinib. The structure is claimed in patent US10561657B2, as a Janus kinase (JAK) inhibitor [4]. It later transpired that rovadicitinib (TQ05105) was a dual JAK1/2 and Rho kinase (ROCK) 1/2 inhibitor [5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Blair HA. (2026)
Rovadicitinib: First Approval. Drugs, [Epub ahead of print]. [PMID:42243570] |
|
2. Hong M, Ding D, Zhang M, Gao S, Song L, Wu D, Lao S, Yu D, Chang C. (2025)
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study. Eur J Pharmacol, 1005: 178032. [PMID:40752760] |
|
3. Ipek Y, Kilic B, Gunay UB, Eskazan AE. (2023)
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis. Expert Opin Investig Drugs, 32 (10): 931-940. [PMID:37811861] |
|
4. Li Z, Xiao D, Hu Y, Dai L, Duan X, Sun Y, Peng Y, Kong F, Luo H, Han Y et al.. (2022)
Pyrrolopyrimidine compound. Patent number: US10561657B2. Assignee: Centaurus Biopharma Co Ltd Chia Tai Tianqing Pharmaceutical Group Co Ltd Lianyungang Runzhong Pharmaceutical Co Ltd. Priority date: 16/12/2014. Publication date: 18/02/2022. |
|
5. Zhao YM, Luo Y, Shi JM, Wang SQ, Wang CK, Jiang EL, Liang C, Zhu XY, Zhang XJ, Meng FK et al.. (2025)
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD. Blood, 145 (24): 2857-2872. [PMID:40009501] |